Published in Gene Therapy Weekly, June 28th, 1999
Studies in mice involved attaching a cloned gene responsible for human clotting factor VIII - a protein severely deficient in people with hemophilia A - to a genetically-engineered virus called AAV. A single injection of the virus led to a gradual increase in blood levels of factor VIII, which have remained stable for 11 months.
"This is the first result in animals demonstrating the efficacy of this approach to hemophilia A," said Dr. Christopher E. Walsh,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.